Teerawattanapong Nipaporn, Srisawat Lanraphat, Narkdontri Tassanee, Yenchitsomanus Pa-Thai, Tangjittipokin Watip, Plengvidhya Nattachet
Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Siriraj Center of Research Excellence for Diabetes and Obesity (SiCORE-DO), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Heliyon. 2024 Feb 24;10(5):e27047. doi: 10.1016/j.heliyon.2024.e27047. eCollection 2024 Mar 15.
This study aims to investigate the effects of the rs7903146 and rs2233580 (R192H) variants associated with T2D on the therapeutic efficacies of various HAs in patients with T2D after follow-up for 3 years.
A total of 526 patients who were followed up at the Diabetic Clinic of Siriraj Hospital during 2016-2019 were enrolled. The variants rs7903146 and rs2233580 (R192H) were genotyped using the RNase H2 enzyme-based amplification (rhAmp) technique and the associations between genotypes and glycemic control after treatments with different combinations HA were evaluated using Generalized Estimating Equations (GEE) analysis.
Patients who carried rs7903146C/T + T/T genotypes when they were treated with biguanide alone had significantly lower fasting plasma glucose (FPG) than those of the patients who carried the C/C genotype (p = 0.01). Patients who carried the rs2233580 G/G genotype when they were treated with sulfonylurea alone had significantly lower FPG than those of the patients who carried G/A + A/A genotypes (p = 0.04).
Genotypes of rs7903146 and rs2233580 (R192H) variants associated with T2D influence the therapeutic responses to biguanide and sulfonylurea. Different genotypes of these two variants might distinctively affect the therapeutic effects of HAs. This finding provides evidence of pharmacogenetics in the treatment of diabetes.
本研究旨在调查与2型糖尿病相关的rs7903146和rs2233580（R192H）变体对2型糖尿病患者接受各种降糖药物治疗3年后疗效的影响。
纳入2016年至2019年期间在诗里拉吉医院糖尿病门诊接受随访的526例患者。使用基于核糖核酸酶H2酶的扩增（rhAmp）技术对rs7903146和rs2233580（R192H）变体进行基因分型，并使用广义估计方程（GEE）分析评估不同组合降糖药物治疗后基因型与血糖控制之间的关联。
单独使用双胍类药物治疗时，携带rs7903146 C/T + T/T基因型的患者空腹血糖（FPG）显著低于携带C/C基因型的患者（p = 0.01）。单独使用磺脲类药物治疗时，携带rs2233580 G/G基因型的患者FPG显著低于携带G/A + A/A基因型的患者（p = 0.04）。
与2型糖尿病相关的rs7903146和rs2233580（R192H）变体的基因型影响对双胍类药物和磺脲类药物的治疗反应。这两种变体的不同基因型可能对降糖药物的治疗效果有显著影响。这一发现为糖尿病治疗中的药物遗传学提供了证据。
